Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087129 | 1.00 | CA2 (0.42) | CA2POLBHTTLMNAHCRTR1 | |
| SCHEMBL6087694 | 1.00 | CA2 (0.42) | CA2POLBHTTLMNAHCRTR1 | |
| SCHEMBL6583410 | 0.93 | HTT (0.41) | CA2POLBHTTLMNAHCRTR1 | |
| SCHEMBL6583233 | 0.93 | HTT (0.41) | CA2POLBHTTLMNAHCRTR1 | |
| SCHEMBL6087133 | 0.88 | FKBP1A (0.48) | POLBHTT | |
| SCHEMBL6087699 | 0.88 | FKBP1A (0.48) | POLBHTT | |
| SCHEMBL6084684 | 0.88 | FKBP1A (0.48) | POLBHTT | |
| SCHEMBL6583228 | 0.83 | CCR4 (0.48) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6583408 | 0.83 | CCR4 (0.48) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6167541 | 0.83 | CA2 (0.40) | CA2POLBHTR1ASIGMAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | claimed |
| US-7045629-B2 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2006-05-16 | — | — | US | disclosed |
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | PAH, HPD, CYP3A43 | CA2 28/4885POLB 3249/4885HTT 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.